These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 29366352)

  • 1. Gene Therapy for Hemophilia and Duchenne Muscular Dystrophy in China.
    Liu X; Liu M; Wu L; Liang D
    Hum Gene Ther; 2018 Feb; 29(2):146-150. PubMed ID: 29366352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral vector-mediated gene therapies.
    Hollinger K; Chamberlain JS
    Curr Opin Neurol; 2015 Oct; 28(5):522-7. PubMed ID: 26263476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
    Blankinship MJ; Gregorevic P; Chamberlain JS
    Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duchenne muscular dystrophy: genome editing gives new hope for treatment.
    Crispi V; Matsakas A
    Postgrad Med J; 2018 May; 94(1111):296-304. PubMed ID: 29386334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges.
    Rando TA
    Biochim Biophys Acta; 2007 Feb; 1772(2):263-71. PubMed ID: 17005381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
    Duan D
    Mol Ther; 2018 Oct; 26(10):2337-2356. PubMed ID: 30093306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
    Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
    Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and Biochemical Assessment of Gene Therapy in the Canine Model of Duchenne Muscular Dystrophy.
    Hakim CH; Pérez-López D; Burke MJ; Teixeira J; Duan D
    Methods Mol Biol; 2023; 2587():255-301. PubMed ID: 36401035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
    Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
    Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the smallest virus to the biggest gene: marching towards gene therapy for duchenne muscular dystrophy.
    Duan D
    Discov Med; 2006 Jun; 6(33):103-8. PubMed ID: 17234143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in gene therapy for Duchenne muscular dystrophy.
    Clemens PR; Duncan FJ
    Curr Neurol Neurosci Rep; 2001 Jan; 1(1):89-96. PubMed ID: 11898504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via
    Matsuzaka Y; Hirai Y; Hashido K; Okada T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
    Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
    Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [How safe is gene therapy? : Second death after Duchenne therapy].
    Horn S; Fehse B
    Inn Med (Heidelb); 2024 Jun; 65(6):617-623. PubMed ID: 38748280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.